ArticleNature medicine2018
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.
Erratum issued 2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 404 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
404citing papers in PubMed, 2 pooled it
28.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901): A Prospective Multicenter Study
Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study
Who cites it
404 citing papers in PubMed, 2 syntheses or guidelines pooled it, 692 citations in OpenAlex.
- The role of microbiota derived metabolites in modulating diabetic inflammation: a systematic review.Journal of molecular histology · 2026Pooled it
- Dietary modulation of pubertal timing: gut microbiota-derived SCFAs and neurotransmitters orchestrate hypothalamic maturation via the gut-brain axis.Journal of endocrinological investigation · 2025Pooled it
- The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial.Journal of translational medicine · 2025Trial
- Glucocorticoid-induced changes of the gut microbiota and metabolic markers in healthy young men: Outcome of a randomized controlled trial.Cell reports. Medicine · 2025Trial
- Gut microbiota shaping fatty liver disease progression.Life science alliance · 2027Review
- Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host.Gut microbes · 2026Review
- Gut bacteria and their metabolites may influence our decisions, intelligence, cognition, and consciousness.Gut microbes · 2026Review
- An Attention-Residual Hybrid CNN for CT-Based Multiclass Classification of Alcohol-Related Liver Disease: Differential Diagnosis Against HBV-Related Cirrhosis.Diagnostics (Basel, Switzerland) · 2026Article
- Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The Role of Gut Microbiota in Liver Regeneration After Partial Hepatectomy: New Evidence From Animal and Human Studies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD.Journal of gastroenterology · 2026Article
- Phenylacetic Acid, a Gut Microbially Produced Metabolite, Reduces Atherosclerosis Burden and Impacts Host Lipid Homeostasis.Journal of the American Heart Association · 2026Article
- Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease: From Dysbiosis to Metagenomic Insights and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Modulating the Gut-Liver Axis: Anti-Inflammatory Mechanisms of Probiotics and Prebiotics in MASLD.Probiotics and antimicrobial proteins · 2026Review
- NovelGut · 2026Article
- Faecalibacterium-derived spermidine mediates the amelioration of fatty liver hemorrhagic syndrome by inulin in laying hens.NPJ biofilms and microbiomes · 2026Article
- Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules · 2026Review
- Microbiota transplantation and multi-omics profiling integration unveil the mechanism of Alistipes communis-driven abdominal fat deposition in chickens.Journal of animal science and biotechnology · 2026Article
- Red Ginseng Extract Intake and Changes in Metabolite Profiles, Gut Microbiota, and Immune Responses of Healthy Rats.Nutrients · 2026Article
344 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
35 authors at 6 institutions in 4 countries.
Lesley HoylesDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-6418-342X
José-Manuel Fernández-RealDepartment of Endocrinology, Diabetes and Nutrition and Department of Medicine, Hospital of Girona "Dr Josep Trueta", Universitat of Girona and CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain. jmfreal@idibgi.org.
Massimo FedericiDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, Rome, Italy. federicm@uniroma2.it.ORCID http://orcid.org/0000-0003-4989-5194
Matteo SerinoInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.ORCID http://orcid.org/0000-0003-4644-8532
James AbbottDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-7701-4249
Julie CharpentierInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Christophe HeymesInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Jèssica Latorre LuqueDepartment of Endocrinology, Diabetes and Nutrition and Department of Medicine, Hospital of Girona "Dr Josep Trueta", Universitat of Girona and CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0002-7603-1458
Elodie AnthonyInstitut Cochin Inserm U1016 CNRS UMR 8104, Université Paris Descartes, Paris, France.
Richard H BartonDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.
Julien ChillouxDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-0384-7317
Antonis MyridakisDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-1690-6651
Laura Martinez-GiliDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-5271-9672
José Maria Moreno-NavarreteDepartment of Endocrinology, Diabetes and Nutrition and Department of Medicine, Hospital of Girona "Dr Josep Trueta", Universitat of Girona and CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain.
Fadila BenhamedInstitut Cochin Inserm U1016 CNRS UMR 8104, Université Paris Descartes, Paris, France.
Vincent AzalbertInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Vincent Blasco-BaqueInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Josep PuigDepartment of Endocrinology, Diabetes and Nutrition and Department of Medicine, Hospital of Girona "Dr Josep Trueta", Universitat of Girona and CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain.
Gemma XifraDepartment of Endocrinology, Diabetes and Nutrition and Department of Medicine, Hospital of Girona "Dr Josep Trueta", Universitat of Girona and CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain.
Wifredo RicartDepartment of Endocrinology, Diabetes and Nutrition and Department of Medicine, Hospital of Girona "Dr Josep Trueta", Universitat of Girona and CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain.
Christopher TomlinsonDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-8634-6111
Mark WoodbridgeDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-0650-9751
Marina CardelliniDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, Rome, Italy.
Francesca DavatoDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, Rome, Italy.
Iris CardoliniDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, Rome, Italy.
Ottavia PorzioDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Paolo GentileschiDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Frédéric LopezInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Fabienne FoufelleSorbonne Universités, UPMC Univ Paris 06, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.
Sarah A ButcherDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-4494-5124
Elaine HolmesDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.
Jeremy K NicholsonDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK.
Catherine PosticInstitut Cochin Inserm U1016 CNRS UMR 8104, Université Paris Descartes, Paris, France.
Rémy BurcelinInstitut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France. remy.burcelin@inserm.fr.
Marc-Emmanuel DumasDivision of Integrative Systems Medicine and Digestive Diseases, Department of Surgery and Cancer, Imperial College London, London, UK. m.dumas@imperial.ac.uk.ORCID http://orcid.org/0000-0001-9523-7024
Imperial College London · GBUniversité Toulouse III - Paul Sabatier · FRInstituto de Salud Carlos III · ESUniversity of Rome Tor Vergata · ITCentre National de la Recherche Scientifique · FRSorbonne Université · FR
Funding
Medical Research Council MR/L01632X/1Medical Research Council MR/M501797/1
Abstract
Hepatic steatosis is a multifactorial condition that is often observed in obese patients and is a prelude to non-alcoholic fatty liver disease. Here, we combine shotgun sequencing of fecal metagenomes with molecular phenomics (hepatic transcriptome and plasma and urine metabolomes) in two well-characterized cohorts of morbidly obese women recruited to the FLORINASH study. We reveal molecular networks linking the gut microbiome and the host phenome to hepatic steatosis. Patients with steatosis have low microbial gene richness and increased genetic potential for the processing of dietary lipids and endotoxin biosynthesis (notably from Proteobacteria), hepatic inflammation and dysregulation of aromatic and branched-chain amino acid metabolism. We demonstrated that fecal microbiota transplants and chronic treatment with phenylacetic acid, a microbial product of aromatic amino acid metabolism, successfully trigger steatosis and branched-chain amino acid metabolism. Molecular phenomic signatures were predictive (area under the curve = 87%) and consistent with the gut microbiome having an effect on the steatosis phenome (>75% shared variation) and, therefore, actionable via microbiome-based therapies.
Indexed as
MetagenomicsAnimalsCells, CulturedCohort StudiesConfounding Factors, EpidemiologicDiabetes MellitusFecal Microbiota TransplantationFemaleHepatocytesHumansMetabolomeMetabolomicsMiceMicrobiotaNon-alcoholic Fatty Liver DiseaseObesity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03990753ClinicalTrials.gov
NCT04543643ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.